High-
risk health workers
First
responders
All-
ages at high risk
Older
adults congregate/overcrowded
K-
12 teachers, staff, childcare workers
Critical
workers in high-risk settings
Moderate
comorbid conditions
Homeless
shelters
Incarcerated
people and staff
All
older adults
Younger
adults
Children
Workers
in important industries
Everyone
else
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
% of total population by priority group
% of population with vaccine-induced immunity by deal under scenario A assumptions:
Moderna
BioNTech/Pfizer
Johnson & Johnson (Janssen)
Oxford/AstraZeneca
Novavax
Sanofi/GSK
Valneva
Total across all deals